Across TCGA pan-cancer cohorts, CENATAC mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CENATAC data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CENATAC mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CENATAC expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, GBM, and HNSC are the cancer types where CENATAC mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.898	0.310	.006	13	view →
GBM	DFS	Quartile	All	0.457	0.770	.009	11	view →
HNSC	DFS	Quartile	All	0.271	1.000	.024	9	view →
LSCC	DFS	Tertile	All	0.988	0.877	.008	8	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: CENATAC tumor-vs-normal RNA expression · all CENATAC data types